recodetx.comHealthcare / BioTech & PharmaFounded: 2015Funding to Date: $367.57MM
Develops precision genetic medicines and therapies focused on Cystic Fibrosis, Primary Ciliary Dyskinesia and various cancers and central nervous system diseases.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
01/10/2023 | Series B | $259.8MM | $xx.xx | $576.08MM | Matrix Capital Management, Pfizer Ventures, EcoR1 Capital, Sanofi Ventures, Tekla Capital Management, Superstring Capital, NS Investment, OrbiMed, Vida Ventures, MPM Capital, Colt Ventures, Hunt Technology Ventures, Osage University Partners, Bayer, Amgen, CF Foundation | |
Price per Share
$xx.xx
Shares Outstanding
28,137,525
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
5.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Matrix Capital Management, Pfizer Ventures, EcoR1 Capital, Sanofi Ventures, Tekla Capital Management, Superstring Capital, NS Investment, OrbiMed, Vida Ventures, MPM Capital, Colt Ventures, Hunt Technology Ventures, Osage University Partners, Bayer, Amgen, CF Foundation
|
||||||
01/10/2023 | Series A-3 | $15MM | $xx.xx | $576.08MM | Matrix Capital Management, Pfizer Ventures, EcoR1 Capital, Sanofi Ventures, Tekla Capital Management, Superstring Capital, NS Investment, OrbiMed, Vida Ventures, MPM Capital, Colt Ventures, Hunt Technology Ventures, Osage University Partners, Bayer, Amgen, CF Foundation | |
Price per Share
$xx.xx
Shares Outstanding
1,252,854
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
5.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Matrix Capital Management, Pfizer Ventures, EcoR1 Capital, Sanofi Ventures, Tekla Capital Management, Superstring Capital, NS Investment, OrbiMed, Vida Ventures, MPM Capital, Colt Ventures, Hunt Technology Ventures, Osage University Partners, Bayer, Amgen, CF Foundation
|
||||||
03/26/2020 | Series A-5 | $5.32MM | $xx.xx | $160.84MM | OrbiMed Advisors, Colt Ventures, MPM Capital, Vida Ventures, Hunt Technology Ventures, Osage University Partners | |
Price per Share
$xx.xx
Shares Outstanding
1,407,617
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
5.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
OrbiMed Advisors, Colt Ventures, MPM Capital, Vida Ventures, Hunt Technology Ventures, Osage University Partners
|
||||||
03/26/2020 | Series A-4 | $5.36MM | $xx.xx | $160.84MM | OrbiMed Advisors, Colt Ventures, MPM Capital, Vida Ventures, Hunt Technology Ventures, Osage University Partners | |
Price per Share
$xx.xx
Shares Outstanding
1,851,927
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
5.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
OrbiMed Advisors, Colt Ventures, MPM Capital, Vida Ventures, Hunt Technology Ventures, Osage University Partners
|
||||||
03/26/2020 | Series A-1 | $80MM | $xx.xx | $160.84MM | OrbiMed Advisors, Colt Ventures, MPM Capital, Vida Ventures, Hunt Technology Ventures, Osage University Partners | |
Price per Share
$xx.xx
Shares Outstanding
14,296,176
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
5.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
OrbiMed Advisors, Colt Ventures, MPM Capital, Vida Ventures, Hunt Technology Ventures, Osage University Partners
|
||||||
12/16/2016 | Series A-2 | $2.08MM | $xx.xx | $4.63MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
1,126,512
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
5.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|